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First Documentation of Rickettsia conorii Infection 
(Strain Indian Tick Typhus) in a Traveler 
To the Editor: Spotted fever group rickettsiae are gram-neg-
ative intracellular bacilli associated with arthropods, mainly 
ticks, as vectors. To date, 12 tick-borne rickettsioses are rec-
ognized worldwide, seven since 1991 (1). Indian tick typhus 
(ITT) is a tick-borne rickettsiosis prevalent in India (1). 
Although the disease has been recognized clinically, cases 
have been documented only rarely, and then mainly with 
nonspecific serologic tools, such as the Weil Felix test. We 
report the first serologically documented case of infection 
caused by Rickettsia conorii (strain ITT) in a French traveler 
returning from India.
In September 1999, a 25-year-old woman living in 
France was hospitalized with a 4-day history of fever, head-
ache, vertigo, malaise, and disturbance of vision, followed 3 
days later by arthromyalgia and a rash. On the day of admis-
sion, she had returned from a 1-month stay in India. She 
reported a number of bites by unidentified arthropods during 
her trip. Her temperature was 40°C with relative bradycar-
dia (72/minute). Physical signs included pharyngitis, tran-
sient epistaxis, bilateral conjunctivitis, and a maculopapular 
rash including petechiae, mostly on the trunk and lower 
limbs but also on her palms and the soles of her feet. There 
was no inoculation eschar.
Clinical laboratory findings included increased alanine 
aminotransferase (56 UI/L), lactate dehydrogenase (1,008 
UI/L), C-reactive protein (130 mg/L), and erythrocyte sedi-
mentation rate (74 mm/hour). The kaolin cephalin time was 
43 seconds (control 34 seconds). Hemoglobin was 10.5 g/dL, 
and the mean corpuscular volume was 99.7 fL. Repeated 
blood smears, blood cultures, and a stool bacterial culture 
disclosed no pathogens. Serologic tests, including assays for 
rickettsioses, were negative. 
The patient received 5 days of empirical doxycycline 
treatment (200 mg/day), intravenously for the first 2 days 
because of vomiting. She became afebrile 2 days after ther-
apy was begun. Subsequently, all her symptoms resolved. 
Ten days later, the immunofluorescence assay for antibodies 
reactive with spotted fever group rickettsiae showed 
increased levels of immunoglobulin (Ig) M (1:256) and IgG 
(1:1024) against R. conorii Seven and IgM (1:512) and IgG 
(1:2048) against R. conorii ITT. Serologic findings were com-
pleted by Western blot performed with acute-phase serum, 
which showed a band of approximately 135 kDa against R. 
conorii ITT, but not R. conorii Seven. Cross-absorption stud-
ies were performed with convalescent-phase sera. Sera were 
absorbed with R. conorii Seven and R. conorii ITT antigens 
and then tested by immunofluorescence assay for remaining 
antibodies reactive to both antigens. When absorption was 
performed with R. conorii ITT antigens, serologic testing was 
negative for antibodies to both R. conorii Seven and R. 
conorii ITT antigens. However, when absorption was done 
with R. conorii Seven antigens, subsequent serologic testing 
was negative for antibodies to R. conorii Seven, but antibod-
ies to R. conorii ITT remained (1:100). Thus, Western blot-
ting and cross-absorption strongly supported that the 
infection was due to R. conorii ITT. 
Although ITT was clinically described at the beginning 
of the century, the etiologic agent has never been isolated 
from patients in India, nor has a case been diagnosed by 
strain-specific serologic testing. A spotted fever group rick-
ettsia was isolated in 1950 from a brown dog tick, Rhipiceph-
alus sanguineus, collected in India (2) and assumed to be the 
agent causing ITT. It was designated as Rickettsia conorii, 
the agent of Mediterranean spotted fever, which occurs all 
around the Mediterranean and is transmitted by the same 
tick species. However, the disease as it appears in India dif-
fers from the common description of Mediterranean spotted 
fever. The rash is frequently purpuric, and an inoculation 
eschar at the bite site is rarely found, as in this case. The dis-
ease as known in India is mild to moderately severe, 
although our case may be considered severe (1,3,4). 
Strain differences within the species R. conorii may 
account for differences in clinical presentation. Although dif-
ferent isolates of R. conorii can be distinguished antigeni-
cally (5-7), molecular taxonomic methods demonstrated 
recently that these rickettsiae are closely related and cluster 
together (8-10). Thus, the species is considered by many as 
R. conorii, including four serovars: R. conorii with three type 
strains, Seven being the one most commonly identified in our 
laboratory in isolates from France, Portugal, North Africa 
(D. Raoult, unpub. data), Kenya, and Morocco (apparently a 
unique isolate); R. conorii Indian tick typhus; R. conorii 
Astrakhan, and R. conorii Israel. 
Immunofluorescence is the reference diagnostic method 
for associated rickettsioses, but cross-reactivity among 
related isolates confounds interpretation of serologic tests. 
Cross-absorption tests, especially in conjunction with West-
ern blot immunoassays, can be used to determine the rickett-
sia species involved, as reported in this case. The higher 
sensitivity of Western blots compared with immunofluores-
cence has been demonstrated previously in our laboratory; it 
is frequently positive in acute-phase sera when antibodies 
cannot be detected by immunofluorescence (11). In this case, 
we used R. conorii Seven as the type strain of R. conorii 
because it is most closely related to R. conorii ITT phyloge-
netically (10). Although these techniques are time-consum-
ing and available only in specialized reference laboratories, 
they provide data of importance that allow a better under-
standing of the epidemiology of rickettsioses.
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Multidrug-Resistant Pseudomonas aeruginosa 
Producing PER-1 Extended-Spectrum Serine-ß-
Lactamase and VIM-2 Metallo-ß-Lactamase
To the Editor: In Pseudomonas aeruginosa, secondary beta-
lactamases with extended substrate specificity can be 
responsible for acquired resistance to the most powerful 
antipseudomonal beta-lactams, such as expanded-spectrum 
cephalosporins and carbapenems (1). A number of these 
enzymes have been described, including extended-spectrum 
serine-beta-lactamases (ESBLs) of groups 2be and 2d (e.g., 
PER-1 and various OXA-type enzymes) (2,3) and metallo-
beta-lactamases of group 3 (e.g., IMP-1 and the recently 
described VIM-1 and VIM-2 enzymes) (2,4,5). The secondary 
ESBLs can degrade penicillins, expanded-spectrum cepha-
losporins, and monobactams (but not carbapenems) and are 
often susceptible to serine-beta-lactamase inhibitors (1-3). 
The secondary metallo-beta-lactamases, on the other hand, 
are notable for their carbapenemase activity and can 
degrade virtually all beta-lactams except monobactams, 
while being resistant to the currently available inhibitors 
(1,2,5,6).
On March 2000, a multidrug-resistant P. aeruginosa 
(isolate VA-182/00) was isolated in pure culture from a bron-
chial washing of a 58-year-old patient with multiple 
myeloma. The patient had been admitted 15 days earlier to 
the Varese University Hospital with a diagnosis of pneumo-
nia and had been treated with ciprofloxacin (0.5 g twice a 
day) plus piperacillin (2 g three times a day) for 12 days, and 
then with imipenem/cilastatin (0.5 g three times a day). No 
cultures of respiratory tract specimens were done earlier in 
hospitalization. Multiple myeloma had been diagnosed in 
1997, and the patient had been treated with multiple cycles 
of antiproliferative chemotherapy and had received autolo-
gous peripheral blood stem cell transplantation. According to 
clinical records, P. aeruginosa had not been isolated previ-
ously during this patient’s protracted illness. In vitro suscep-
tibility testing showed that the P. aeruginosa isolate was 
resistant to mezlocillin, ceftazidime, cefepime, aztreonam, 
imipenem, meropenem, gentamicin, tobramycin, netilmicyn 
(MICs, >128 µg/mL), amikacin (MIC, 64 µg/mL), ciprofloxa-
cin and levofloxacin (MICs, >32 µg/mL). Only piperacillin 
and piperacillin/tazobactam had MIC values slightly lower 
than the breakpoints for resistance (64 µg/mL and 48/4 µg/
mL, respectively), although–considering the normal MICs of 
piperacillin for susceptible P. aeruginosa (2-8 µg/mL)–it was 
evident that the isolate also had considerable biological 
resistance to these drugs. A double disk-diffusion test, car-
ried out with standard disks placed 20 mm apart (center-to-
center), showed synergy between clavulanate and aztre-
onam. The treatment was changed to piperacillin/tazobac-
tam (4 g four times a day), and a slow recovery ensued over a 
30-day period. The patient died 3 months later following a 
relapse of the underlying malignancy.
The unusually high carbapenem MICs exhibited by VA-
182/00 suggested production of a secondary metallo-beta-lac-
tamase, while the synergy between clavulanate and aztre-
onam suggested production of a secondary serine ESBL. A 
crude extract of that isolate, assayed spectrophotometrically 
(7), exhibited imipenem-hydrolyzing activity (94 nmol/min/
mg protein, inhibited by EDTA) as well as aztreonam-hydro-
lyzing activity (11 nmol/min/mg protein, resistant to EDTA). 
Analytic isoelectric focusing (IEF) of the extract, followed by 
development with the nitrocefin chromogenic substrate (7), 
showed three bands of beta-lactamase activity of pIs 5.4, 5.6, 
and 6.3, suggesting the presence of at least three different 
secondary enzymes. A colony-blot hybridization with probes 
for the blaIMP, blaVIM, and blaPER resistance genes (all of 
which have been previously detected in P. aeruginosa clinical 
isolates from the same hospital [8,9; Luzzaro F, unpub. 
data]) yielded positive results with both the blaVIM and the 
blaPER probes. Amplification of the resistance genes by poly-
merase chain reaction (PCR) with primers VIM/DIA-f (5'-
CAgATTgCCgATggTgTTTgg) and VIM/DIA-r (5'-AggTgggC-
CATTCAgCCAgA) for blaVIM genes (4,5) and BLAPER-f (5'-
gggACA(g/A)TC(g/C)(g/T)ATgAATgTCA) and BLAPER-r (5'-
ggg(C/T)(g/C)gCTTAgATAgTgCTgAT) for blaPER genes (9), 
yielded amplicons of the expected sizes (522 and 966 bp, 
respectively). Direct amplicon sequencing identified the two 
beta-lactamase determinants as blaVIM-2 (5) and blaPER-1 
(10), respectively, a finding consistent with the pIs 5.6 and 
5.4 beta-lactamase bands detected in IEF (3,5). Conjugative 
transfer of the resistance determinants to Escherichia coli 
proved unsuccessful. In a Southern blot analysis of total 
undigested DNA from VA-182/00, both the blaVIM and bla-
PER probes apparently hybridized to the chromosomal DNA 
band; no plasmid bands recognized by either probe were 
detected. A PCR experiment with primers OXA10-f (5'-ggAA-
CAAAgAgTTCTCTgCC) and OXA105-r (5'-TTAgCCAC-
CAATgATgCC(C/T)TC), suitable for amplification of blaOXA 
genes of the OXA-10 group, did not yield an amplicon of the 
expected size (719 bp), suggesting that the pI 6.3 beta-lacta-
mase band detected by IEF did not correspond to an enzyme 
of this group.
This is the first observation of a P. aeruginosa clinical 
isolate simultaneously producing a secondary PER-1 ESBL 
and a secondary metallo-beta-lactamase. The finding, 
observed in a hospital where both the resistance genes 